Request Deal Involvement
SK Capital to invest in Swixx BioPharma at a €1.5bn valuation.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
commercial advisors
Clearview Healthcare Partners
financial advisors
Rothschild & Co
pr advisors
Gregory FCA
legal advisors
Bar & Karrer
debt providers
Ares Management
legal advisors
Kirkland & Ellis
accounting advisors
KPMG
accounting advisors
Ernst & Young
financial advisors
Centerview Partners
financial advisors
Jefferies & Company
legal advisors
Walder Wyss
commercial advisors
Boston Consulting Group
or
Principals
bidder
SK CAPITAL PARTNERS
target
SWIXX BIOPHARMA
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite